Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

AUTOMATED AND RAPID MICROBIOLOGICAL TESTS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Automated and Rapid Microbiological Tests in US$ Million by the following End-Use Segments: Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests), and Non-Clinical Applications. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets.The report profiles 93 companies including many key and niche players such as Abbott Laboratories, Abbott Diagnostics, Alere Inc., Becton Dickinson and Company, bioMerieux SA, bioMerieux, Inc., Bio-Rad Laboratories, Inc., Cellabs Pty Ltd, Celsis International Plc., Coris BioConcept, F. Hoffmann-La Roche Ltd., Gen-Probe Inc., MedMira Inc., Meridian Biosciences, Inc., Orasure Technologies, Inc., Orion Diagnostica Oy, Quidel Corporation, Sekisui Diagnostics, Siemens Healthcare Diagnostics, Inc., Thermo Fisher Scientific, Inc., Remel, Inc., and Oxoid Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-1093
Price : $4500
Companies : 93
Pages : 660
Date : October 2011
Market Data Tables : 193
Status: * New Report

Complimentary Report Insights:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  AUTOMATED AND RAPID MICROBIOLOGICAL TESTS (Complete Report) Pages : 660   | $4500
 
  1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.....I-15 $295  
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2  
   Data Interpretation & Reporting Level.....I-3
Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Clinical Applications.....I-4
Automated Identification and Susceptibility Systems.....I-4
Automated Blood Culture Systems.....I-4
  
   Automated Tuberculosis Systems.....I-5
Streptococcal Infection Rapid Tests.....I-5
GC/Chlamydia Rapid Tests.....I-5
Other Automated & Rapid Microbiological Tests.....I-5
Non-Clinical Applications.....I-5
  
  2. INDUSTRY OVERVIEW.....II-610 $950  
   Outlook.....II-6
Evolutionary Battle Against Bugs Drives Market Future.....II-6
Automated Microbiological Tests: A Pesky Gray Area in the Clinical Diagnostics
  Market.....II-6
1$100
   Traditional Rapid Microbiological Tests Destined to Go Out With the Old.....II-7
A Current & Future Analysis.....II-7
1$100
   Segmental Perspective.....II-8
Clinical Applications.....II-8
Non-Clinical Applications.....II-8
Macro: The Big Picture.....II-8
1$100
   Deciding the Market’s Future.....II-9
A Holistic Peek into a Few Noteworthy Trends.....II-9
1$100
   Biotechnology & Rapid Microbial Tests.....II-101$100
   Automated & Rapid Microbiological Tests: “Current Market Stance”.....II-11
A Business Case for Automated & Rapid Microbiological Testing.....II-11
1$100
   Near Patient Testing: An Offshoot of Rapid Microbiological Tests.....II-12
Pros & Cons of Near Patient Testing.....II-12
1$100
   Role of Near Patient Testing in Reducing Antibiotic Resistance in Humans.....II-13
The Pre/Post Microbial Rapid Testing Era: A Review.....II-13
1$100
   Market Structure.....II-14
Competitive Setup of the Diverse Automated & Rapid Microbiology Products
  Market.....II-14
1$100
   Competitive Landscape.....II-15
Table 1: World Market for Microorganism Identification and Resistance Tests by Leading Players (2010): Market Share Breakdown of Value Share for BioMérieux; Becton, Dickinson and Co; and Others (includes corresponding Graph/Chart).....II-15

Table 2: World In-Vitro Diagnostics (IVD) Market by Leading Players (2010): Market Share Breakdown for Roche, Siemens, Abbott Diagnostics, Becton Dickinson, Beckman Coulter and Others (includes corresponding Graph/Chart).....II-15

Table 3: World Blood Screening Market by Leading Players (2010): Market Share Breakdown for Gen-Probe/Novartis, Roche, and Others (includes corresponding Graph/Chart).....II-15
1$350
  3. MARKET TRENDS & ISSUES.....II-1610 $595  
   Advancements in Molecular Diagnostics - A Boon or a Threat.....II-16
Leading Companies in Molecular Diagnostics Market.....II-16
Antibiotic Resistant Bacteria Throws the Spotlight On Microbial Testing.....II-16
1$100
   Instant Detection of Pathogens – A New Epoch in the Fight for Survival.....II-17
Lower Cost Rapid Tests Built on Multiple Sampling Modalities – Gaining
  Momentum.....II-17
“Time Constraints?” - Rapid Tests to the Rescue.....II-17
1$100
   Rapid HIV Tests: A New Age Diagnostic Weapon Against the Killer Disease.....II-18
Accuracy/Reliability of Home HIV Testing: A Bone of Contention.....II-18
1$100
   Development of Near Patient Test Kits: A Market Driven Phenomenon.....II-19
Near Patient Test Kits: A Rumination of Possibilities.....II-19
1$100
   Automated Blood Culture Systems: A Winning Edge in the Fight Against
  Bacteremia.....II-20
Leading Food Processors Resort to Rapid Microbiological Testing.....II-20
1$100
   Impact of Food Scares on Rapid Microbiological Tests Market.....II-211$100
   Demand for Microbiological Tests & Level of QC in the Food Industry.....II-221$100
   Rapid Tests Creating Brighter Avenues in Food Microbiology Testing Market.....II-23
Dire Need to Nip Operating Costs Throws the Spotlight on Rapid Tests.....II-23
1$100
   Key Advantages/Benefits of Rapid Microbiological Tests on Food.....II-24
Food Packages of the Future Ingrained with Microbial Alert Systems.....II-24
Technology Innovations in Rapid Food Microbial Testing: A Historic Brief.....II-24
1$100
   Obtaining Regulatory Approval – A Major Non-Technical Hindrance.....II-251$100
  4. FACTORS INFLUENCING THE MARKET.....II-264 $295  
   Continuing Biological Warfare with Pathogens Sparks Market Growth.....II-26
Innovative Products – A Key Growth Strategy.....II-26
Other Market Drivers in a Capsule.....II-26
Low Turnaround Times Skyrocket Demand.....II-26
Greater Patient Awareness.....II-26
1$100
   Rising Incidence of STDs Kindles Universal Market Acceptance.....II-27
Ultra-Rapid HIV-Screening Tests- A Strong Fight against HIV-Epidemic.....II-27
Validation of Rapid Microbiological Tests: An Imperative Prerequisite.....II-27
1$100
   Non-Conformance to Testing Requirements: A Weighty Concern.....II-281$100
   Influenza – Boosting Rapid Test Prospects.....II-291$100
  5. PRODUCT/TECHNOLOGY OVERVIEW.....II-3011 $950  
   Automated & Rapid Microbiological Tests: A Definition.....II-30
Benefits of Automated & Rapid Microbiological Tests.....II-30
1$100
   Classification of Rapid Microbiological Test Methods.....II-31
How Does a Rapid Test Work?.....II-31
1$100
   Sample Preparation – A Key Procedure.....II-32
Automated Identification and Susceptibility Systems.....II-32
1$100
   Automated Blood Culture Systems.....II-33
Automated Tuberculosis Systems.....II-33
Microminiaturization of Diagnostic Tests: How Is It Effected?.....II-33
1$100
   Advantages of Microminiaturisation:.....II-34
Acid-Fast Microscopy – The Forerunner of Rapid Tests.....II-34
Gram's Stain: A Time-Honored & Rapid Method to Detect Pathogens in Blood.....II-34
1$100
   Enabling Technologies of Automated & Rapid Microbiological Tests.....II-35
Growth-based Technologies.....II-35
Viability-based Technologies.....II-35
1$100
   Cellular-Component or Artifact-based Technologies.....II-36
Genomics/ Proteomics.....II-36
Microarrays/Microfluidics.....II-36
1$100
   DNA Microchips/Probes.....II-37
Polymerase Chain Reaction (PCR).....II-37
1$100
   Immunoassay.....II-38
Immunoassay Escalates into Diverse Fields of Diagnostic Testing.....II-38
Nucleic Acid Testing (NAT).....II-38
1$100
   Nucleic Acid Probes.....II-39
Signal-Amplified Tests.....II-39
Nucleic Acid Amplification Tests.....II-39
1$100
   Traditional Methods with Computer-Aided Imaging.....II-40
Combination Methods.....II-40
1$100
  6. END-USE APPLICATION ANALYSIS.....II-4114 $1450  
   Applications in Clinical Investigations.....II-41
STD Rapid Tests.....II-41
GC/Chlamydia Rapid Tests.....II-41
1$100
   HIV Rapid Tests.....II-421$100
   HIV Facts & Figures.....II-43
Table 4: Global Prevalence of HIV Infection by Region: 2007 & 2008 (includes corresponding Graph/Chart).....II-43
1$350
   Table 5: Global HIV Related Deaths by Region: 2007 & 2008 (includes corresponding Graph/Chart).....II-441$350
   Table 6: Global Distribution of HIV Prevalence, Incidence and Mortality: 2008 (includes corresponding Graph/Chart).....II-45
Advantages of Rapid HIV Testing.....II-45
Disadvantages of Rapid HIV Testing.....II-45
1$350
   Syphilis Rapid Tests.....II-46
Respiratory Rapid Tests.....II-46
RSV/ Influenza Rapid Tests.....II-46
1$100
   Tuberculosis Rapid Tests.....II-47
Group A beta Hemolytic Streptococcus Rapid Tests.....II-47
Mononucleosis Rapid Tests.....II-47
1$100
   Streptococcus Rapid Tests.....II-48
Streptococcus A Rapid Tests.....II-48
Streptococcus B Rapid Tests.....II-48
1$100
   Gastrointestinal Rapid Tests.....II-49
Giardia Lamblia Rapid Tests.....II-49
H. Pylori Rapid Tests.....II-49
1$100
   Cryptosporidium Rapid Tests.....II-50
C. Difficile Rapid Tests.....II-50
Applications in Non-Clinical Investigations.....II-50
1$100
   Food/Water Safety Tests.....II-51
Food Safety Testing: A Lucrative Application Area.....II-51
1$100
   Rapid Microbiological Methods in Pharmaceutical Sector.....II-52
Limitations of RMMs.....II-52
1$100
   Advantages of RMMs.....II-53
Applications in Pharmaceutical Sector.....II-53
Environmental Tests.....II-53
1$100
   Other Miscellaneous Applications.....II-541$100
  7. PRODUCT INNOVATIONS/INTRODUCTIONS.....II-5518 $1450  
   BioControl Systems Develops PCR for Detecting Non-O157 Serotypes of STEC.....II-55
InDevR Introduces New Virus Counter.....II-55
MicroPhage Receives Approval from FDA for KeyPath™ MRSA/MSSA Blood Culture Test –
  BT.....II-55
1$100
   Health Canada Approves DuPont’s BAX® System Real-Time Assay.....II-56
Neogen Receives Approval from AOAC for Reveal 2.0 Test.....II-56
Life Technologies and University of Pennsylvania School of Veterinary Medicine
  Introduce TaqMan® Salmonella enteritidis Detection Kit.....II-56
AdvanDX Obtains 510(k) Clearance from US FDA for GNR Traffic Light™ PNA FISH®.....II-56
Pall Introduces GeneDisc Rapid Microbiology System.....II-56
1$100
   Abbott Laboratories Introduces PLEX-ID™ Biothreat Assay.....II-57
bioMerieux Receives FDA Clearance for NucliSENS EasyQ MRSA.....II-57
BD Launches BD Max™ Open System.....II-57
1$100
   Luxcel Biosciences and Mocon Develop GreenLight™900 Series.....II-58
Bruker Launches pTD™ for Homeland Security.....II-58
Hygiena International Launches EnSURE.....II-58
1$100
   Researchers at University of Georgia Develop Pneumonia Diagnostic Test.....II-59
BD Diagnostics Obtains Approval from FDA for BD MAX™ GBS Assay.....II-59
bioMérieux Receives Approval for TEMPO® STA from AOAC and AFNOR.....II-59
Bruker Introduces MALDI Sepsityper™ Kit.....II-59
AdvanDx Introduces GNR Traffic Light™ PNA FISH®.....II-59
1$100
   ZyGEM Launches Microbial Fingerprinting Diagnostic Technology.....II-60
BD Diagnostics Launches BD BACTEC™ MGIT™ 320 Mycobacteria Culture System.....II-60
Particle Measuring Systems Launches BioLaz™ Real-Time Microbial Monitor.....II-60
1$100
   NanoLogix Launches Quick-Test Product Line.....II-61
MOCON Introduces GreenLight™ Screening System.....II-61
Life Technologies Unveils MicroSEQ® Rapid Microbial Identification System.....II-61
IDEXX Laboratories Launch Enterolert®-DW in Europe.....II-61
1$100
   Alere Rolls Out three Cardiac Testing Solutions.....II-62
Millipore Introduces New Milliflex Quantum Rapid Microbiological Test Method.....II-62
BD Diagnostics Adds Automated Microbiology Specimen Processor to its Diagnostic
  Portfolio.....II-62
1$100
   Roche Introduces New Automatic Clinical Laboratory System, Cobas®4800.....II-63
Thermo Fisher Scientific Launches an Automated Photometric Method.....II-63
Thermo Fisher Scientific Introduces Salmonella Rapid Culture Method.....II-63
1$100
   BD Receives FDA Clearance for BD ProbeTec Amplified DNA Assays on BD Viper
  System.....II-64
Oxoid Introduces Xpect® Flu A&B.....II-64
Oxoid Extends ProSpecT Range.....II-64
1$100
   Oxoid Launches ELISA Systems Test Kits Range.....II-65
Oxoid Introduces Brilliance VRE Agar and Brilliance ESBL Agar.....II-65
1$100
   Oxoid Launches RapID Kits.....II-66
Inverness Medical Innovations Introduces C. DIFF QUIK CHEK COMPLETETM Rapid
  Test.....II-66
1$100
   Celsis International Launches Celsis ReACTTM.....II-67
Roche Diagnostics Introduces LightCycler® Mycobacterium Detection Kit.....II-67
1$100
   bioMérieux Introduces NucliSENS EasyQ® HIV-1 v2.0.....II-681$100
   Celsis International Unveils RapiScreenTM Beverage.....II-69
Siemens Launches MicroScan Synergies plus® gram-positive ID/MIC and MIC Combination
  Panels.....II-69
Oxoid Introduces IDEIATM Norovirus.....II-69
1$100
   Oxoid Introduces Salmonella PrecisTM Process.....II-70
Remel Offers FDA Approved RPMI 1640 Agar w/MOPS and 2% Glucose.....II-70
Oxoid Launches Rapid MDG Broth.....II-70
1$100
   Lonza Introduces microCompass TYMC (Total Yeast and Mould Count) Detection Kit.....II-71
Inverness Medical Introduces Determine HIV-1/2 Ag/Ab Combo.....II-71
1$100
   Meridian Bioscience Rolls Out Two New Rapid Tests for Detecting Epstein-Barr
  Virus.....II-72
Oxoid Introduces Staph Plus System for Identifying Staphylococcal Species.....II-72
1$100
  8. PRODUCT INNOVATIONS/INTRODUCTIONS IN RECENT PAST – A PERSPECTIVE BUILDER.....II-7311 $950  
   Siemens Healthcare Diagnostics Launches MicroScan® WalkAway® plus Diagnostic
  Microbiology Systems.....II-73
Bio-Rad Launches a Rapid test for Screening MRSA, MRSASelect™ test, in US.....II-73
bioMérieux Introduces VIDAS®, an automated Clostridium difficile A & B Toxins Detection
  Test.....II-73
1$100
   Oxoid Launches Remel Wellcolex® Colour Tests for Testing Shigella, E. coli O157 and
  Salmonella.....II-74
Siemens Healthcare Diagnostics Obtains Health Canada Approval for its VERSANT 440
  Molecular System.....II-74
Oxoid Unveils Remel Xpect™ Clostridium Difficile Toxin A/B Test.....II-74
Neogen Introduces Soleris System.....II-74
1$100
   ATCC Introduces Authenticult™ Quality Control Microbiological Testing Tool.....II-75
Bio-Rad Introduces New EBV Kits.....II-75
Roche Seeks FDA Marketing Approval for Hepatitis C Virus Test.....II-75
Roche Seeks US FDA Approval for its Cobas TaqScreen MPX Test.....II-75
1$100
   FDA Clears Usage of TIGRIS® System for Testing WNV in Donated Blood.....II-76
FDA Approves ImmunoCard STAT!® EHEC for Detecting E. coli Infection.....II-76
bioMérieux Introduces TEMPO® Quality Indicator Testing System.....II-76
Biotrace Introduces Tecra Unique Campylobacter Rapid Test.....II-76
1$100
   bioMérieux Introduces TEMPO® EB test for Enterobacteriaceae.....II-77
Roche Unveils Elecsys TORCH Assays.....II-77
Roche Diagnostics Introduces Cobas TaqMan MTB Test in Japan.....II-77
bioMérieux Develops Advanced Colorimetry™ NH Card.....II-77
1$100
   Roche Introduces Rapid LightCycler SeptiFast Sepsis Test across EU.....II-78
Oxoid Launches New Rapid Test for Salmonella Detection in Food Products.....II-78
Oxoid Unveils New Contact Plate Design.....II-78
FDA Approves Fluconazole Susceptibility Tests from BioMérieux.....II-78
1$100
   Polysciences Unveils New Microbiological & Bacterial Detection Applications.....II-79
Researchers Develop New Rapid MODS Test for TB Detection.....II-79
Dade Behring Unveils Automated Quadriga BeFree System.....II-79
FDA Approves Abbott PRISM® HBsAg Assay.....II-79
1$100
   Bayer’s EHIV Test Receives FDA Clearance.....II-80
Gen-Probe Obtains FDA Approval to Use Aptima Test on Additional Specimens.....II-80
Roche Diagnostics’ cobas TaqScreen MPX Test Receives CE Mark Approval.....II-80
Cepheid Introduces Rapid Xpert® MRSA Test in Europe.....II-80
1$100
   Bio-Rad Widens Culture Media with Addition of RAPID'Salmonella.....II-81
Chemogen Develops New Tuberculosis Rapid Test.....II-81
bioMerieux Rolls Out VIDAS® LDUO Test.....II-81
Zonda Develops New Rapid Test for Chlamydia.....II-81
MedMira Launches MiraCare Rapid HIV Test.....II-81
1$100
   STMicroelectronics and Mobidiag Unveil Lab-On-Chip.....II-82
Vermicon Launches ScanVIT-Legionella Rapid Test Kit.....II-82
New Line of Rapid Microbial Detection Systems from Centrus.....II-82
OraSure Rolls Out OraQuick ADVANCE.....II-82
Abbott Unveils Automated HCV Test.....II-82
1$100
   ViroMed Rolls Out Rapid PCR Tests for Detecting Influenza and Respiratory
  Pathogens.....II-83
Biophage Pharma Offers Service for Microbiological Testing.....II-83
bioMerieux Releases New Rapid Test for Nosocomial Infections.....II-83
bioMerieux Widens Product Portfolio with Addition of TEMPO® System.....II-83
1$100
  9. RECENT INDUSTRY ACTIVITY.....II-8414 $950  
   Sekisui Chemical Acquires Diagnostic Products Business of Genzyme.....II-84
Dynacare Laboratories Acquires Bruker MALDI Biotyper System.....II-84
Magellan Biosciences Enters into Partnership with miacom Diagnostics.....II-84
Lonza Signs Distribution Agreement with Roche.....II-84
1$100
   BD Enters into Collaboration with Bruker Daltonics.....II-85
Seegene Enters into Partnership with Molzym.....II-85
bioMérieux Enters into Partnership with Shanghai Institutes for Biological
  Sciences.....II-85
Becton, Dickinson and Company Acquires Global Rights to Market Micro PRO.....II-85
1$100
   Rapid Micro Biosystems Enters Into Partnership with Life Technologies.....II-86
DuPont and U.S. Department of Agriculture to Collaborate for New Microbiological
  Test.....II-86
bioMérieux and Biocartis Enter into Partnership.....II-86
BD Diagnostics Collaborates with Lonza Group.....II-86
1$100
   Rapid Micro Biosystems Signs Contract with BARDA.....II-87
Shimadzu and bioMérieux Enter into Partnership.....II-87
Micro Identification Technologies and OSI Optoelectronics Sign Agreement.....II-87
Inverness Medical Adopts New Corporate Identity.....II-87
Thermo Fisher Acquires Ahura Scientific.....II-87
1$100
   Don Whitley Signs Distribution Agreement with Zisys.....II-88
Charm Sciences Acquires MLX Microplate Luminometer Product Line from Dynex
  Technologies.....II-88
1$100
   Alpha Analytical Acquires Boston Analytical Inc......II-89
Roche Group Acquires Genentech.....II-89
Roche Acquires Innovatis AG.....II-89
3M Takes Over Biotrace International.....II-89
1$100
   Lab21 Buys Majority Stake in Biotec Laboratories.....II-90
Vacci-Test Acquires Maxivet.....II-90
bioMerieux Acquires PML Microbiologicals.....II-90
1$100
   3M Acquires Food Diagnostics AS.....II-91
Becton, Dickinson and Company Receives License for its GeneOhmTM from Health
  Canada.....II-91
BD Diagnostics Receives CE Marking for BD GeneOhmTM VanR Test.....II-91
1$100
   bioMérieux Bags AOAC Research Institute's Performance- Tested Methods SM
  Approval.....II-92
MedMira Receives Sales Approval of Multiplo HBV/HIV/HCV Rapid Tests Market.....II-92
Schering-Plough Inks International Collaboration Agreement with OraSure
  Technologies.....II-92
1$100
   Roche Selects Quidel's Influenza Test.....II-93
Quidel Enters into Global Alliance with bioMerieux.....II-93
Premier's QUEST Selects Remel SpectraTM MRSA.....II-93
Thermo Fisher Scientific and MedAssets Supply Chain Systems Enter into a Supply
  Agreement.....II-93
1$100
   Thermo Fisher Scientific Bags FDA Approval for SpectraTM MRSA.....II-94
Advantest to Take Over Credence Systems.....II-94
DSM Food Specialties to Acquire CMT Srl.....II-94
Sysmex Signs Agreement with bioMerieux.....II-94
1$100
   Nanogen Enters into Definitive Agreement with Elitech Group.....II-95
Silliker Acquires Majority Stake in EGI Laboratory.....II-95
BD Establishes New Rapid Diagnostic Products Manufacturing Facility in China.....II-95
1$100
   Quidel Corporation Obtains CLIA Waiver from US FDA for its QuickVue(R) RSV
  Test.....II-96
Siemens Obtains US FDA Approval for its VERSANT™ 440 Molecular System.....II-96
bioMérieux to Market Wescor’s Customized Slide Stainer Instruments under bioMérieux
  Brand.....II-96
Schering-Plough and OraSure Ink Collaboration Agreement for Developing Rapid Oral HCV
  Test.....II-96
1$100
   Abbott Obtains US FDA Approval for its Automated HTLV-I/HTLV-II Blood Screening
  Test.....II-97
Quidel and bioMérieux Form a Long-term Alliance in Rapid Diagnostic Tests.....II-97
BD Diagnostics Obtains US FDA Approval for BD GeneOhm™ StaphSR Assay.....II-97
1$100
  10. CORPORATE ACTIVITY IN RECENT PAST – A PERSPECTIVE BUILDER.....II-9819 $950  
   Siemens Acquires Dade Behring.....II-98
Concateno Acquires Euromed.....II-98
Meridian Bioscience Obtains US FDA Approval for Two New Rapid Tests.....II-98
Thermo Fisher Scientific Teams Up with KBA for Expanding its Microbiology Business
  Division in Lenexa.....II-98
1$100
   OraSure and SCMS Enter into an Agreement for Supplying OraQuick(R) HIV Test to PEPFAR
  Countries.....II-99
Abbott Obtains US FDA Approval for its Fully Automated PRISM® HCV Test.....II-99
Gen-Probe Obtains US FDA Approval for its PROCLEIX® TIGRIS® System for Testing Donated
  Blood.....II-99
AdvanDx Ropes In bioMérieux for Distributing its Rapid Diagnostic Tests in US.....II-99
1$100
   3M and Gen-Probe Join Hands to Develop Rapid Molecular Tests For Detecting
  HAIs.....II-100
Gen-Probe’s PROCLEIX® TIGRIS® System Obtains US FDA Approval for Screening Donated
  Blood for West Nile Virus.....II-100
3M Acquires Acolyte Biomedica.....II-100
1$100
   Formation of Siemens Medical Solutions Diagnostics.....II-101
bioMérieux Bags Contract to Provide VITEK® 2 System for Scottish NHS Labs.....II-101
1$100
   bioMérieux Licenses NorChip’s HPV Test Technology for Cervical Cancer.....II-102
bioMérieux in Strategic Agreement with Cepheid for Sepsis Assays.....II-102
3M Health Care Creates New Medical Diagnostics Unit.....II-102
1$100
   Schering-Plough & OraSure to Develop Rapid Oral HCV Test.....II-103
3M Acquires Biotrace International.....II-103
Siemens Acquires DPC.....II-103
1$100
   Oxoid Acquires Microbiology Business Activities of Dako.....II-104
Inverness Acquires IDT and Thermo BioStar.....II-104
BMD in Agreement with MND for Research on Diagnostic Tests.....II-104
Cepheid Wins CDC Contract to Develop Rapid Bird Flu Virus Detection Test.....II-104
1$100
   Dutch Government Grants €7.9 Million to FIND.....II-105
FIND and Hain to Develop Rapid Test for MDR and XDR TB.....II-105
3M & Gen-Probe Ally for Developing Rapid Molecular Tests for Food Safety.....II-105
1$100
   Bio View Inks Three-Year Distribution Agreement with Abbott Molecular.....II-106
Bodycote Acquires Foodscan Laboratories.....II-106
Cepheid Bags STTR Funding for Development of Rapid TB Test.....II-106
1$100
   Abbott and Verax in Distribution Agreement for Verax Platelet PGD® Test.....II-107
BSL Supplies ABBOTT PRISM® System to Blood Donor Testing Centers.....II-107
Abbott & ARC in Agreement for Automated Blood Screening Tests.....II-107
1$100
   BD to Set Up Production Facility for Rapid Diagnostic Products in China.....II-108
BD Diagnostics Delivers STI Testing Products to BioReference.....II-108
Meridian Licenses LAMP Diagnostic Test Technology from Eiken.....II-108
OraSure Inks Multi-Year Purchase Contract with New York City.....II-108
1$100
   Abbott Inks Single-Source Agreement with Novation for HIV Test.....II-109
Neogen Takes Over Centrus International.....II-109
Becton, Dickinson and Company Acquires GeneOhm Sciences.....II-109
Inverness Medical Innovations Makes a Synergetic Purchase of ACON
  Laboratories.....II-109
1$100
   Quest Diagnostics Strikes Deal with BD Diagnostics.....II-110
Novation Inks Pact with Abbott for Rapid HIV-1/2 Antibody Test.....II-110
TREK Diagnostic and Novation Inks Agreement.....II-110
Clinton Foundation Inks Agreement with Four Companies to Cut Prices.....II-110
Chembio Obtains FDA Approval for HIV 1/2 Stat-Pak and Sure Check HIV 1/2 Rapid Test
  PMAs.....II-110
1$100
   Roche’s LightCycler SeptiFast Test Attains CE Mark.....II-111
Zonda Expands Distribution of Products in Europe.....II-111
OraSure Wins Rapid HIV Tests Order.....II-111
MedMira Secures Orders for Rapid HIV Tests.....II-111
Cepheid Collaborates with Foundation for Innovative Diagnostics.....II-111
1$100
   Chembio Obtains Clearance for Rapid HIV Tests in Kenya.....II-112
Genesis Bioventures Bags US Patent for Rapid Prion- Detection Assay.....II-112
MedMira Obtains CE Mark for MiraCare.....II-112
Setema to Distribute Chembio’s Rapid HIV Tests in Ethiopia.....II-112
Clinton Foundation HIV/AIDS Initiative Selects Chembio to Provide Rapid HIV
  Tests.....II-112
Quidel Acquires immunochemical Fecal Occult Blood Test.....II-112
Xact Aid Snaps Up STD Alert.....II-112
1$100
   Grant Life Sciences Acquires Rapid Tests from AccuDx.....II-113
Millipore Ties Up with Gen-Probe.....II-113
Foundation for Innovative New Diagnostics forms Collaboration with Eiken
  Chemical.....II-113
WayPoint and Global Rapid Diagnostic Leader Enter into an Agreement.....II-113
Akers Biosciences Enters into a Distribution Agreement with Alco Industries.....II-113
1$100
   Celsis and BioVentures Enter into Licensing Agreement.....II-114
Thermo Electron Inks Pact with Genomic Profiling Systems.....II-114
Abbott and OraSure Enters into Agreement for OraQuick ADVANCE Rapid HIV-1/2
  Test.....II-114
bioMérieux Signs Agreement with Novel Diagnostics.....II-114
Dade Behring Bags FDA Approval for Antimicrobial Susceptibility Test Panels.....II-114
1$100
   OraSure Bags HCV Patent License from Chiron and Ortho- Clinical Diagnostics.....II-115
BD Diagnostics Receives FDA Approval for BD Directigen™ EZ Flu A+B Test.....II-115
BD Diagnostics Bags FDA Clearance for BBL™ CHROMagar™ MRSA Product.....II-115
MedMira Obtains Rights to Market Rapid HIV Tests in Guizhou Province, China.....II-115
Gen-Probe Obtains FDA Clearance for PROCLEIX® West Nile Virus Assay.....II-115
Medical Services International Secures Clearance for Rapid Test Kits.....II-115
Medical Services International Receives Exclusive Marketing Rights for TB Test
  Kit.....II-115
1$100
   Adaltis Receives Orders for HIV Rapid Tests from China.....II-116
MedCap Bags Exclusive Distribution Rights for Syphilis Rapid Test.....II-116
Genomic Profiling Systems Obtains NIAID Funds to Develop Testing Platform.....II-116
Gen-Probe Obtains US Patent for Automated Process for Nucleic Acid Testing.....II-116
Bio-Rad Receives Approval for HIV-1/HIV-2 Rapid Test.....II-116
1$100
  11. FOCUS ON SELECT GLOBAL PLAYERS.....II-1179 $595  
   Abbott Laboratories (USA).....II-117
Abbott Diagnostics (USA).....II-117
Alere Inc. (US).....II-117
1$100
   Becton Dickinson and Company (USA).....II-118
bioMerieux SA (France).....II-118
1$100
   bioMerieux, Inc. (USA).....II-119
Bio-Rad Laboratories, Inc (USA).....II-119
Cellabs Pty Ltd (Australia).....II-119
1$100
   Celsis International Plc (UK).....II-120
Coris BioConcept (Belgium).....II-120
F. Hoffmann-La Roche Ltd. (Switzerland).....II-120
1$100
   Gen-Probe Inc. (USA).....II-121
MedMira, Inc. (Canada).....II-121
1$100
   Meridian Biosciences, Inc. (USA).....II-122
Orasure Technologies, Inc. (USA).....II-122
Orion Diagnostica Oy (Finland).....II-122
1$100
   Quidel Corp. (USA).....II-123
Sekisui Diagnostics (Japan).....II-123
1$100
   Siemens Healthcare Diagnostics, Inc. (USA).....II-124
Thermo Fisher Scientific, Inc. (USA).....II-124
Remel, Inc. (USA).....II-124
1$100
   Oxoid Limited (UK).....II-1251$100
  12. GLOBAL MARKET PERSPECTIVE.....II-126   
   Table 7: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart).....II-1261$350
   Table 8: World Historic Review for Automated and Rapid Microbiological Tests by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1271$350
   Table 9: World 15-Year Perspective for Automated and Rapid Microbiological Tests by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1281$350
   Table 10: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1291$350
   Table 11: World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1301$350
   Table 12: World 15-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1311$350
   Table 13: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used – Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests and Other Automated & Rapid Microbiological Tests Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1321$350
   Table 14: World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used – Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests and Other Automated & Rapid Microbiological Tests Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1331$350
   Table 15: World 15-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used – Percentage Breakdown of Revenues for Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests and Other Automated & Rapid Microbiological Tests for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1341$350
   Table 16: World Recent Past, Current & Future Analysis for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1351$350
   Table 17: World Historic Review for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1361$350
   Table 18: World 15-Year Perspective for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1371$350
   Table 19: World Recent Past, Current & Future Analysis for Automated Blood Culture Systems in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart).....II-1381$350
   Table 20: World Historic Review for Automated Blood Culture Systems in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1391$350
   Table 21: World 15-Year Perspective for Automated Blood Culture Systems in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1401$350
   Table 22: World Recent Past, Current & Future Analysis for Automated Tuberculosis Systems in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart).....II-1411$350
   Table 23: World Historic Review for Automated Tuberculosis Systems in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1421$350
   Table 24: World 15-Year Perspective for Automated Tuberculosis Systems in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1431$350
   Table 25: World Recent Past, Current & Future Analysis for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart).....II-1441$350
   Table 26: World Historic Review for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1451$350
   Table 27: World 15-Year Perspective for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1461$350
   Table 28: World Recent Past, Current & Future Analysis for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart).....II-1471$350
   Table 29: World Historic Review for GC/Chlamydia Rapid Tests (*) in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1481$350
   Table 30: World 15-Year Perspective for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1491$350
   Table 31: World Recent Past, Current & Future Analysis for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1501$350
   Table 32: World Historic Review for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1511$350
   Table 33: World 15-Year Perspective for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1521$350
   Table 34: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart).....II-1531$350
   Table 35: World Historic Review for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1541$350
   Table 36: World 15-Year Perspective for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1551$350
  13. THE UNITED STATES.....II-15614 $3850  
   A. Market Analysis.....II-156
A Current & Future Analysis.....II-156
Rapid Microbiology Tests - A Competitive Profile.....II-156
Consolidation in the Automated and Rapid Microbiological Tests Market.....II-156
1$100
   Bioterrorism Tests – Gaining Prominence.....II-157
Tracking Trends Across Product Segments.....II-157
STD Rapid Tests.....II-157
Market Share Trends of Leading Players.....II-157
1$100
   Table 37: Leading Players in the US Market for GC/Chlamydia Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Gen-Probe, Abbott, Becton Dickinson and Roche (includes corresponding Graph/Chart).....II-158

Table 38: Leading Players in the US Market for Chlamydia Rapid Tests (2010) – Percentage Breakdown of Value Sales by Company for Thermo Fischer Scientific, Alere ,and Quidel (includes corresponding Graph/Chart).....II-158

Table 39: Leading Players in the US Market for Syphilis Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, Alere, and Others (includes corresponding Graph/Chart).....II-158
Leading Players in HIV Rapid Testing Market.....II-158
1$350
   Gastrointestinal Rapid Tests.....II-159
Market Share Data of Leading Players.....II-159
Table 40: Leading Players in the US Market for C. Difficile Rapid Tests (2010) –Percentage Breakdown of Value Sales by Company for Alere, Meridian Biosciences, BioSite, Becton Dickinson, Thermo Fischer Scientific, and Others (includes corresponding Graph/Chart).....II-159

Table 41: Leading Players in the US Market for Cryptosporidium Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Remel, Meridian Biosciences, and Becton Dickinson (includes correspondingGraph/Chart).....II-159
1$350
   Table 42: Leading Players in the US Market for Rotavirus Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Meridian Biosciences, Thermo Fisher Scientific, and Others (includes corresponding Graph/Chart).....II-160

Table 43: Leading Players in the US Market for Giardia Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Remel, Meridian Biosciences, and Becton Dickinson (includes corresponding Graph/Chart).....II-160
Respiratory Rapid Tests.....II-160
Competition.....II-160
1$350
   Market Share Data of Leading Players.....II-161
Table 44: Leading Players in the US Market for Influenza Rapid Tests (2010) – Percentage Breakdown of Value Sales by Company for Quidel, Becton Dickinson, Thermo Fischer Scientific and Others (includes corresponding Graph/Chart).....II-161

Table 45: Leading Players in the US Market for RSV Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, Binax,,Thermo Fischer Scientific and Others (includes corresponding Graph/Chart).....II-161

Table 46: Leading Players in the US Market for Tuberculosis Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Gen-Probe and Becton Dickinson (includes corresponding Graph/Chart).....II-161
1$350
   Table 47: Leading Players in the US Market for M. Pneumoniae Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Meridian Biosciences, and Remel, Inc. (includes corresponding Graph/Chart).....II-162

Table 48: Leading Players in the US Market for Mononucleosis Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Alere, Remel, Quidel, and Others (includes corresponding Graph/Chart).....II-162
Streptococcus Infection Rapid Tests.....II-162
1$350
   Market Share Data of Leading Players.....II-163
Table 49: Leading Players in the US Market for Streptococcus A Rapid Tests (2010) -Percentage Breakdown of Value Sales by Company for Quidel, Thermo Fischer Scientific, Becton Dickinson, and Others (includes corresponding Graph/Chart).....II-163
A Peek into the Testing Practices of the US Food Industry.....II-163
1$350
   B. Market Analytics.....II-164
Table 50: US Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non- Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart).....II-164
1$350
   Table 51: US Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification& Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1651$350
   Table 52: US 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1661$350
   Table 53: US Recent Past, Current & Future Analysis for Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart).....II-1671$350
   Table 54: US Historic Review for Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1681$350
   Table 55: US 15-Year Perspective for Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1691$350
  14. EUROPE.....II-1709 $1995  
   A. Market Analysis.....II-170
A Current & Future Analysis.....II-170
European Market Primer.....II-170
What Drives the Requirement Patterns of End-Users?.....II-170
1$100
   Competitive Profile.....II-171
Trends & Issues.....II-171
Proliferation of Automated, and Rapid Tests in Europe.....II-171
1$100
   European Automated Market.....II-172
Probe Tests: “A Crack in the Future of Rapid Tests”.....II-172
Trends Across Product Segments.....II-172
GC/Chlamydia Rapid Tests.....II-172
Streptococcal Infection (Strep A) Rapid Tests.....II-172
Automated Tuberculosis Systems Market.....II-172
1$100
   B. Market Analytics.....II-173
Table 56: European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region – France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-173
1$350
   Table 57: European Historic Review for Automated & Rapid Microbiological Tests by Geographic Region – France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1741$350
   Table 58: European 15-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region – Percentage Breakdown of Revenues for France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1751$350
   Table 59: European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1761$350
   Table 60: European Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1771$350
   Table 61: European 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1781$350
  14a. FRANCE.....II-1794 $950  
   A. Market Analysis.....II-179
A Current & Future Analysis.....II-179
bioMerieux: A Key Player.....II-179
1$100
   B. Market Analytics.....II-180
Table 62: French Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non- Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 includes corresponding Graph/Chart).....II-180
1$350
   Table 63: French Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1811$350
   Table 64: French 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1821$350
  14b. GERMANY.....II-1834 $950  
   A. Market Analysis.....II-183
A Current & Future Analysis.....II-183
Competitive Structure.....II-183
1$100
   B. Market Analytics.....II-184
Table 65: German Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non- Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart).....II-184
1$350
   Table 66: German Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1851$350
   Table 67: German 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1861$350
  14c. ITALY.....II-1874 $950  
   A. Market Analysis.....II-187
A Current & Future Analysis.....II-187
1$100
   B. Market Analytics.....II-188
Table 68: Italian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart).....II-188
1$350
   Table 69: Italian Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1891$350
   Table 70: Italian 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1901$350
  14d. THE UNITED KINGDOM.....II-1914 $950  
   A. Market Analysis.....II-191
A Current & Future Analysis.....II-191
Increasing Incidence of MRSA Spur Growth in Rapid Diagnostics.....II-191
1$100
   B. Market Analytics.....II-192
Table 71: UK Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart).....II-192
1$350
   Table 72: UK Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1931$350
   Table 73: UK 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1941$350
  14e. SPAIN.....II-1954 $950  
   A. Market Analysis.....II-195
A Current & Future Analysis.....II-195
1$100
   B. Market Analytics.....II-196
Table 74: Spanish Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non- Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart).....II-196
1$350
   Table 75: Spanish Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1971$350
   Table 76: Spanish 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1981$350
  14f. RUSSIA.....II-1994 $950  
   A. Market Analysis.....II-199
A Current & Future Analysis.....II-199
1$100
   B. Market Analytics.....II-200
Table 77: Russian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-200
1$350
   Table 78: Russian Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-2011$350
   Table 79: Russian 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-2021$350
  14g. REST OF EUROPE.....II-2034 $950  
   A. Market Analysis.....II-203
A Current & Future Analysis.....II-203
1$100
   B. Market Analytics.....II-204
Table 80: Rest of Europe Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-204
1$350
   Table 81: Rest of Europe Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-2051$350
   Table 82: Rest of Europe 15-Year Perspective for Automated & Rapid Microbiological Tests by Product Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-2061$350
  15. REST OF WORLD.....II-2076 $950  
   A. Market Analysis.....II-207
A Current & Future Analysis.....II-207
Latin America.....II-207
Asia-Pacific – The Next Epicenter for the AIDS Epidemic.....II-207
1$100
   Demand for Advanced Microbiology Instruments and Testing Methods Set to Grow in
  India.....II-208
2$200
   B. Market Analytics.....II-210
Table 83: Rest of World Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart).....II-210
1$350
   Table 84: Rest of World Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-2111$350
   Table 85: Rest of World 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-2121$350
COMPETITION 426$995
  
Total Companies Profiled: 93 (including Divisions/Subsidiaries - 109)

Region/Country                 Players


The United States                 67   
Canada                             2
Japan                              3
Europe                            31
     France                        3
     Germany                       6
     The United Kingdom           11
     Italy                         1
     Spain                         1
     Rest of Europe                9
Asia-Pacific (Excluding Japan)     4
Middle-East                        2
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign